Gilead Sciences has signed a definitive agreement to acquire NeXstarPharmaceuticals in an all-stock action. Under the terms of the deal, NeXstar stockholders will receive 0.425 of a share of Gilead for each of their own and based on its average stock price for the 20-day period ended February 26, Gilead values the transaction at approximately $550 million.
The combined company will have three marketed products which currently generate revenues of over $100 million: Ambisome (liposomal amphotericin B) for serious fungal infections, the anticancer agent DaunoXome (daunorubicin citrate) and Vistide (cidofovir injection) used to treat cytomegalovirus retinitis in AIDS patients. It will have seven products in development, most notably Gilead's Preveon (adefovir dipivoxil) for HIV.
John Martin, Gilead's chief executive, said NeXstar's international organization "is particularly attractive...because of its efficient size, specialty focus and track record of market leadership." The new entity will go under the name Gilead Sciences Inc.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze